Gallium Ga 68-Edotreotide PET/MRI in Imaging Patients with Small Bowel Tumors

Inclusion Criteria

• Have histologically or cytologically confirmed small bowel carcinoid tumor
• Receiving a stable dose of octreotide LAR as a part of a treatment regimen for >= 3 months
• Presently planned for ongoing octreotide according to current standard of care for at least 12 months (i.e. throughout the study follow-up period)
• Presently planned for restaging using contrast-enhanced computed tomography (CT) scans at baseline and at least every 6 months, as a part of their standard of care assessments
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of Ga-68-DOTA-TOC administration
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Participants who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• Participants with known brain metastases should be excluded from this clinical trial
• History of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biologic composition to Ga-68-DOTA-TOC or 18F-FLT used in study
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study; breastfeeding mothers are also excluded from this study
• Expected lifespan less than 12 months by investigator assessment
• Previous hypersensitivity reaction to LAR octreotide
• Non-removable hearing aid or dentures, metal intrauterine device (IUD), surgical aneurysm clips, cardiac pacemaker, prosthetic heart valve, neurostimulator, implanted pumps, cochlear implants, metal rods, plates or screws, surgery leaving implanted materials, metal injury to eye, metallic tattoos anywhere on the body, tattoos near the eye and transdermal patches
• History of Meniere’s disease